The healthcare sector might not be at the forefront of exciting developments like artificial intelligence, but because good ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for the ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

With a current dividend yield of 3.2%, AbbVie Inc. ABBV was a key stock in the investor’s portfolio earning $4,800 per month. The stock has gained about 42% over the past year. AbbVie has raised ...

US central bank lowered rates by another 25 basis points on Thursday. AbbVie, Chevron, and Elf Beauty could benefit from ...